Medication shown sits at the center of this dementia and brain health question.

Yes, medications are now demonstrably protecting brain structure in Alzheimer’s patients—and the results are meaningful. Recent FDA-approved medications like Leqembi and Kisunla have been shown to slow cognitive decline in early-stage Alzheimer’s disease by clearing amyloid-beta buildup from the brain. Beyond these established treatments, experimental medications like Leukine have demonstrated the ability to actually stop brain cell death in clinical trials, while drugs like ALZ-801 reduce brain atrophy by as much as 18% compared to placebo.

This marks a significant shift in how we approach Alzheimer’s: from managing symptoms to actively protecting the organ itself. What makes this different from previous treatments is that these medications target the disease’s root cause—the accumulation of toxic proteins and inflammation—rather than just masking cognitive symptoms. For someone in the early stages of Alzheimer’s, this distinction means the difference between slowing memory loss and potentially preventing it. This article explores the medications that are protecting brain structure, how they work, what the evidence shows, and what this means for people and families navigating an Alzheimer’s diagnosis today.

Which FDA-Approved Medications Protect Brain Structure in Alzheimer’s?
How Much Brain Atrophy Can These Medications Actually Prevent?
Emerging Medications That Stop Brain Cell Death
Early-Stage Disease vs. Late-Stage: When These Medications Help Most
Potential Side Effects and Limitations of Brain-Protective Medications
Combination Therapy and Next-Generation Approaches
What This Means for Current and Future Alzheimer’s Care
Conclusion

Which FDA-Approved Medications Protect Brain Structure in Alzheimer’s?

Two medications have received FDA approval specifically for their ability to slow cognitive decline while protecting brain structure: Leqembi (lecanemab) and Kisunla (donanemab). Both work through a similar mechanism—they’re designed to clear amyloid-beta, the sticky protein that accumulates in Alzheimer’s brains and is believed to drive neurodegeneration. When amyloid plaques are removed, the brain’s structural integrity is preserved longer, meaning the hippocampus and cortex don’t shrink as rapidly. These medications were approved in 2025 after years of clinical trials, making them the first disease-modifying treatments that actually demonstrate protection of brain tissue.

The distinction between these two medications matters. Leqembi requires intravenous infusions every two weeks, while Kisunla also requires infusions but on a different schedule. For patients, this means choosing between treatment regimens based on convenience, tolerance, and how well they respond to the drug. The catch is that both medications are approved only for people in the early stages of Alzheimer’s disease—mild cognitive impairment or mild dementia stages—meaning early diagnosis becomes critical. Someone diagnosed after significant cognitive decline has already occurred may not be a candidate, which is why neuropsychological testing and biomarker identification early are so important.

Which FDA-Approved Medications Protect Brain Structure in Alzheimer's?

How Much Brain Atrophy Can These Medications Actually Prevent?

Experimental medications in clinical trials have demonstrated even more dramatic protection against brain shrinkage. ALZ-801, tested in participants with early-stage Alzheimer’s, showed that treated patients experienced approximately 18% less atrophy in the hippocampus—the brain region crucial for memory formation—compared to those receiving placebo. This 18% reduction might sound modest, but in the context of Alzheimer’s disease, where brain atrophy accelerates cognitive decline, slowing it by nearly one-fifth is substantial. It means less rapid deterioration of memory and spatial reasoning.

However, it’s important to recognize that these medications slow atrophy; they don’t stop it entirely or reverse existing damage. If someone has already lost brain tissue to Alzheimer’s, these medications won’t regenerate those neurons. This is why starting treatment early—when brain damage is still in its earliest stages—is crucial. A person who waits until they’re experiencing significant memory problems may find that the disease has progressed too far for these medications to offer meaningful benefit. The race is against time, and the biology of the disease means early intervention is almost always more effective than waiting.

Emerging Medications That Stop Brain Cell Death

Beyond amyloid-clearing treatments, researchers have identified medications that work through entirely different mechanisms. Leukine, a drug originally used for other conditions, showed stunning results in a Colorado study published in December 2025: it can actually halt brain cell death in Alzheimer’s patients. Rather than clearing existing plaques, Leukine appears to protect neurons from the cascade of damage that Alzheimer’s triggers.

This represents a fundamentally different approach—instead of cleaning up after the disease starts, you’re preventing the damage mechanism itself. Another experimental drug, NU-9, works by blocking early neurological damage and reducing neuroinflammation—the destructive inflammatory response in the brain that accelerates Alzheimer’s progression. The research team behind NU-9 found that blocking a specific enzyme from neurons substantially reduces amyloid plaques, suggesting that multiple pathways in the disease can be interrupted. What’s particularly promising about these emerging treatments is that they suggest future Alzheimer’s care may involve combination therapy—using multiple medications simultaneously to attack the disease through several different mechanisms, similar to how HIV or cancer are now treated.

Emerging Medications That Stop Brain Cell Death

Early-Stage Disease vs. Late-Stage: When These Medications Help Most

The most critical practical reality about brain-protective medications is their window of opportunity. All current FDA-approved treatments and most promising experimental medications work best in early-stage disease. Someone with mild cognitive impairment—perhaps noticing occasional memory lapses or struggling with complex tasks—is an ideal candidate. Someone in moderate or advanced dementia, where significant brain damage has already accumulated, is unlikely to see meaningful benefit. This creates a difficult situation: the person who needs memory protection most might be those earliest in the disease, yet many people don’t seek diagnosis until problems become obvious.

This is why biomarker testing has become increasingly important. Rather than waiting for obvious cognitive symptoms, blood tests can now detect amyloid and tau proteins that indicate brain changes years before memory problems appear. Some researchers recommend that people in their 60s with a family history of Alzheimer’s or genetic risk factors like the APOE4 gene variant consider biomarker screening. It sounds aggressive, but it’s the difference between catching the disease when medications can genuinely slow it versus catching it after irreversible damage has occurred. The tradeoff, of course, is dealing with the psychological burden of knowing you have early-stage disease—something each person and family must consider carefully.

Potential Side Effects and Limitations of Brain-Protective Medications

While these medications protect brain structure, they come with real risks that must be weighed carefully. Leqembi and Kisunla carry an FDA black-box warning for amyloid-related imaging abnormalities (ARIA)—meaning that in some patients, the process of clearing amyloid plaques can trigger inflammation or microhemorrhages in the brain. These side effects don’t happen in everyone, but they’ve occurred in clinical trials and can range from asymptomatic (detected only on brain MRI) to serious (headache, confusion, seizures). For some patients, the benefit of slowed cognitive decline outweighs this risk; for others, the risk is unacceptable.

Another critical limitation is that we don’t yet know the long-term effects of these medications beyond the 18-month trial periods used in FDA approval. Someone taking Leqembi for 10 years—if they were to start in their early 60s and continue into their 70s—might experience cumulative effects we haven’t yet documented. Additionally, access remains a major barrier: these medications are expensive, require regular infusions at specialized treatment centers, and many insurance plans haven’t finalized coverage decisions. Geographic location matters too—rural areas may not have infusion centers capable of administering these drugs safely. This creates a two-tiered system where access to brain-protective medications often depends on wealth and location, a reality that’s difficult but important to acknowledge.

Potential Side Effects and Limitations of Brain-Protective Medications

Combination Therapy and Next-Generation Approaches

The future of brain protection in Alzheimer’s likely involves combining medications rather than relying on a single treatment. Just as a heart attack patient might take a statin, an ACE inhibitor, and aspirin simultaneously, Alzheimer’s patients may eventually receive multiple medications targeting different disease mechanisms. Researchers are currently investigating whether combining amyloid-clearing treatments like Leqembi with neuroinflammation reducers like NU-9 or neuroprotective agents like Leukine would produce better results than any single medication alone.

Roche and other major pharmaceutical companies have signaled significant investment in next-generation Alzheimer’s treatments as of 2025-2026, with multiple drugs in late-stage trials. The recognition that early intervention is critical has also prompted development of preventive medications—drugs that might be given to people with Alzheimer’s pathology but no symptoms yet, to prevent cognitive decline from ever occurring. This represents the ultimate evolution: moving from treating symptomatic disease to preventing it entirely in those at genetic or biological risk.

What This Means for Current and Future Alzheimer’s Care

The medications now protecting brain structure in Alzheimer’s patients represent a watershed moment in neurodegenerative disease. For decades, Alzheimer’s was essentially untreatable, with doctors able only to manage cognitive symptoms and behavioral changes. Now, for the first time, we have disease-modifying treatments that address the biological roots of the disease. This should motivate earlier diagnosis, more aggressive screening of at-risk populations, and a fundamental reframing of Alzheimer’s from an inevitably progressive disease to one that can potentially be slowed or, in the future, prevented.

The challenge now is ensuring that these advances translate into real-world benefit for diverse populations. Early indications suggest that amyloid-clearing medications work well in some people and less well in others—likely due to genetic differences and the heterogeneity of “Alzheimer’s disease” itself. As research continues through 2026 and beyond, expect to see more personalized approaches, where genetics and biomarkers guide medication selection. For families facing an Alzheimer’s diagnosis today, the message is clear: early detection and early treatment with brain-protective medications offer genuine hope for slowing decline, making it worth pursuing diagnosis and biomarker testing seriously.

Conclusion

Medications are demonstrably protecting brain structure in Alzheimer’s patients through multiple mechanisms—clearing toxic amyloid proteins, halting neuroinflammation, and preventing brain cell death. FDA-approved treatments like Leqembi and Kisunla slow cognitive decline in early disease, while experimental medications in advanced trials show even more dramatic reductions in brain atrophy and cell death. These represent genuine progress against a disease that has claimed millions of lives with little effective treatment options.

The critical takeaway for anyone concerned about Alzheimer’s is that early detection matters profoundly. These medications work best when started early, before significant brain damage has occurred. If you or a family member has concerns about memory or cognitive changes, pursuing neuropsychological testing and biomarker screening—rather than waiting for obvious problems to develop—gives access to these brain-protective treatments when they’re most effective. We’re at an inflection point where Alzheimer’s is transitioning from inevitably progressive to potentially manageable, but only for those who seek diagnosis and treatment early.